| Reversible Fanconi syndrome in a pediatric patient on deferasirox. | |
| | |
MedLine Citation:
|
PMID: 21298760 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Deferasirox (Exjade®, Novartis) is a widely used oral iron chelator for the treatment of patients with iron overload due to chronic transfusion therapy for diseases such as β-thalassemia and sickle cell disease. Renal side effects of deferasirox are common and include non-progressive increases in serum creatinine, however, the effect of deferasirox on proximal tubule function is unclear. We report one pediatric patient with reversible Fanconi syndrome associated with long-term deferasirox therapy and one patient with mild proximal tubular dysfunction. Kidney and proximal tubular function should be periodically monitored in patients receiving deferasirox throughout their course of therapy. Pediatr Blood Cancer 2011;56:674-676. © 2010 Wiley-Liss, Inc. |
| | |
Authors:
|
Michelle N Rheault; Heather Bechtel; Joseph P Neglia; Clifford E Kashtan |
Publication Detail:
|
Type: Journal Article Date: 2010-12-06 |
Journal Detail:
|
Title: Pediatric blood & cancer Volume: 56 ISSN: 1545-5017 ISO Abbreviation: Pediatr Blood Cancer Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-02-07 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101186624 Medline TA: Pediatr Blood Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 674-6 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Wiley-Liss, Inc. |
Affiliation:
|
Department of Pediatrics, University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota. rheau002@umn.edu. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine...
Next Document: Referral to a specialist paediatric palliative care service in oncology patients.